An intrahepatic transcriptional signature of enhanced immune activity predicts response to peginterferon in chronic hepatitis B

Liver International

Volumn 35, Issue 7, 2015, Pages 1824-1832

  Jansen, Louis ^a,b   de Niet, Annikki ^a,b   Makowska, Zuzanna ^c   Dill, Michael T ^c   van Dort, Karel A ^b   Terpstra, Valeska ^d   Bart Takkenberg, R ^a   Janssen, Harry L A ^e,f   Heim, Markus H ^c   Kootstra, Neeltje A ^b   Reesink, Hendrik W ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF BASEL   (Switzerland)

^d MEDICAL CENTER HAAGLANDEN   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Adefovir; Chronic hepatitis B; Combined response; Gene expression; Liver biopsy; Microarray; Peginterferon alfa 2a; Response marker

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; CCL18 CHEMOKINE; CCL4L1 CHEMOKINE; CHEMOKINE; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HLA ANTIGEN CLASS 2; HLA DMA ANTIGEN; HLA DOA ANTIGEN; HLA DPA1 ANTIGEN; HLA DPB1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB5 ANTIGEN; PEGINTERFERON ALPHA2A; PROTEASE NEXIN; UNCLASSIFIED DRUG; ADENINE; ALPHA INTERFERON; ANTIVIRUS AGENT; GENETIC MARKER; MACROGOL DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; RECOMBINANT PROTEIN;

ACUTE HEPATITIS B; ADULT; ANTIGEN PRESENTATION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHEMOTAXIS; CHIMPANZEE; CHRONIC HEPATITIS B; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE LOCATION; GENE ONTOLOGY; GENETIC TRANSCRIPTION; GENOTYPE; HEPATITIS B VIRUS GENOTYPE A; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNITY; MALE; MEMORY T LYMPHOCYTE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; UPREGULATION; VIRAL CLEARANCE; ANALOGS AND DERIVATIVES; BIOPSY; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; DNA MICROARRAY; DRUG COMBINATION; DRUG EFFECTS; GENETIC MARKER; GENETICS; HEPATITIS B, CHRONIC; IMMUNOLOGY; LIVER; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PROCEDURES; REPRODUCIBILITY; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; VIROLOGY;

ADENINE; ADULT; ANTIVIRAL AGENTS; BIOPSY; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; FEMALE; GENE EXPRESSION PROFILING; GENETIC MARKERS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGANOPHOSPHONATES; PATIENT SELECTION; POLYETHYLENE GLYCOLS; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84931561532     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12768     Document Type: Article

References (25)

1. Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006; 368: 938-45.
2. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
3. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
4. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-75.
5. Janssen HL, van ZM, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-9.
6. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
7. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
8. Thimme R, Dandri M. Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B? J Hepatol 2013; 58: 205-9.
9. Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137: 2002-9.
10. Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699-705.
11. Takkenberg RB, Jansen L, de NA, et al. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-alpha2a and adefovir. Antivir Ther 2013; 18: 895-904.
12. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
13. Takkenberg B, Terpstra V, Zaaijer H, et al. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir. J Gastroenterol Hepatol 2011; 26: 1527-35.
14. Reich M, Liefeld T, Gould J, et al. GenePattern 2.0. Nat Genet 2006; 38: 500-1.
15. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-50.
16. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 2004; 101: 6669-74.
17. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10: 761-3.
18. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2012; 61: 1754-64.
19. TrehanPati N, Geffers R, Sukriti, et al. Gene expression signatures of peripheral CD4 + T cells clearly discriminate between patients with acute and chronic hepatitis B infection. Hepatology 2009; 49: 781-90.
20. Boni C, Laccabue D, Lampertico P, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012; 143: 963-73.
21. Cheng L, Sun X, Tan S, et al. Effect of HLA-DP and IL28B gene polymorphisms on response to interferon treatment in hepatitis B e-antigen seropositive chronic hepatitis B patients. Hepatol Res 2014; 44: 1000-7.
22. O'Brien TR, Kohaar I, Pfeiffer RM, et al. Risk alleles for chronic hepatitis B are associated with decreased mRNA expression of HLA-DPA1 and HLA-DPB1 in normal human liver. Genes Immun 2011; 12: 428-33.
23. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008; 105: 7034-9.
24. Xiao C, Qin B, Chen L, et al. Preactivation of the interferon signalling in liver is correlated with nonresponse to interferon alpha therapy in patients chronically infected with hepatitis B virus. J Viral Hepat 2012; 19: e1-10.
25. Shebl FM, Maeder D, Shao Y, et al. In the absence of HCV infection, interferon stimulated gene expression in liver is not associated with IL28B genotype. Gastroenterology 2010; 139: 1422-4.